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Mutations in the Fatty Acid 2-Hydroxylase Gene
Are Associated with Leukodystrophy
with Spastic Paraparesis and Dystonia
Simon Edvardson,1,2 Hiroko Hama,5 Avraham Shaag,1 John Moshe Gomori,3 Itai Berger,2 Dov Soffer,4
Stanley H. Korman,1 Ilana Taustein,2 Ann Saada,1 and Orly Elpeleg1,*
Myelination is a complex, developmentally regulated process whereby myelin proteins and lipids are coordinately expressed by myeli-
nating glial cells. Homozygosity mapping in nine patients with childhood onset spasticity, dystonia, cognitive dysfunction, and peri-
ventricular white matter disease revealed inactivating mutations in the FA2H gene. FA2H encodes the enzyme fatty acid 2-hydroxylase
that catalyzes the 2-hydroxylation of myelin galactolipids, galactosylceramide, and its sulfated form, sulfatide. To our knowledge, this is
the ﬁrst identiﬁed deﬁciency of a lipid component of myelin and the clinical phenotype underscores the importance of the 2-hydrox-
ylation of galactolipids for myelin maturation. In patients with autosomal-recessive unclassiﬁed leukodystrophy or complex spastic
paraparesis, sequence analysis of the FA2H gene is warranted.Myelin is the lipid-rich organelle that surrounds axons and
constitutes the white matter tracts in the nervous system.1
Myelin is composed of compact membrane layers out of
which the cytoplasm has been extruded. During myelina-
tion, glial cells elaborate processes that contact axons and
spirally enwrap them to form a multilamellar, compact
structure. Thus, the myelin sheath is membrane dense,
which reﬂects its role as an electrical insulator for axonal
membranes. Myelination is a complex, developmentally
regulated process whereby myelin proteins and lipids are
coordinately expressed by myelinating glial cells.2 Myelin
has a water content of ~40% and its dry mass is character-
ized by a high proportion of lipid (70%–85%) and a low
proportion of protein (15%–30%).1 The galactolipids
galactosylceramide (GalC) and its sulfated form, sulfatide,
account for approximately one-third of the lipid content
of the myelin sheath.3 Using homozygosity mapping, we
identiﬁed a defect in the fatty acid 2-hydroxylase (FA2H
[MIM 611026]) that participates in the synthesis of the
fatty acids of myelin galactolipids.
The subjects of the study were nine patients, aged 7–
20 years at the time of writing, from three consanguineous
Arab-Muslim families (Figure 1 and Table 1). All the
patients, four males and ﬁve females, had normal early de-
velopment and all presented at 4–6 years of age with gait
disturbance due to lower-limb spasticity. At this age the
disease did not progress in the two patients from family
3; at 10 and 12 years of age, their disease is restricted to
the lower limbs with no cognitive or speech impairment.
Both patients were ambulatory without external aids,
although they walked with considerable difﬁculty. In
contrast, the disease course was rapidly progressive in the
patients of families 1 and 2, who already required walking
aids at 7 years. When they were 7–12 years of age, theirThe Americaspasticity extended to the upper limbs. Dystonia was evi-
dent from a few years of onset, involving trunk, limbs,
and face and interfering with articulation and swallowing.
Upper-motor-neuron involvement with positive Babinski
sign became evident toward 10 years of age in the patients.
The patients’ cognitive abilities, normal at 6 years of age
with acquisition of reading and writing skills at a normal
pace, deteriorated with age. At 12–14 years of age, these
patients were no longer able to read or write; this deterio-
ration was not attributed to themotor disability or the dys-
arthria. Cerebellar dysfunction with dysmetria and dysdia-
dochokinesis were additionally noted. At midadolescence,
the patients lost ambulation. Patients 122 and 2761 had
transient generalized seizures that resolved spontaneously.
The rest of the physical examination was unremarkable
and there was no clinical or biochemical indication of
other organ involvement.
Laboratory investigations including analysis of plasma
lactate, creatine kinase, ammonia, amino acids, very-long-
chain fatty acids, and urinary organic acids were all normal.
Inmusclemitochondria, the activities of theﬁvemitochon-
drial respiratory-chain complexes were within the control
range, and the pathological and histochemical studies
were normal. The brain stem auditory evoked potentials
of patient 1211 at 18 years of age were normal, but pattern
visual evoked potentials were delayed with a latency of
130ms (Rt) and 123ms (Lt) (normal up to 110ms), suggest-
ing a demyelinating process; electromyography and nerve
conduction velocity were normal. Biopsy of sural nerve of
patient 1211 at age 17 years revealed slight decrease of my-
elinatednerveﬁbers, but the ratioof large to small ﬁbers and
the number of nonmyelinated ﬁbers were normal. Themy-
elin thickness was proportional to the axonal diameter and
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compaction was intact (Figure 2) as evidenced by a space of
15 nanometers between the major dense lines4. Brain MRI
revealed a uniform pattern among patients from families
1 and 2 consisting of prolonged relaxation time of the pos-
terior periventricular whitematter; this pattern was already
present when the patients were 5 years old. With age, the
posterior limbs of the internal capsules and the corticospi-
nal tracts became involved, and there was thinning of the
corpus callosum and the pons with volume depletion of
the cerebellum resulting in ventriculomegaly (Figure 3).
Notably, the cervical spinal cord was entirely spared.
Figure 1. The Families’ Pedigree and Haplotype along the Crit-
ical Region on Chromosome 16
(A) Family 1 pedigree and their haplotype along the critical region
on chromosome 16. Patients’ symbols are filled. Numbered symbols
represent individuals whose DNA samples were available for analy-
sis. The polymorphic microsatellite markers and their chromosomal
locations (in Mb) are given in the upper-left panel. C16 _65.77
stands for hg18_chr16:65767359-65767624, C16_67.21 stands for
hg18_chr16:67214180-67214437, C16_68.20 stands for hg18_
chr16:68218628-68218887, C16_69.20 stands for hg18_chr16:
69227890-69228133, and C16_73.87 stands for hg18_chr16:
73875745-73875997.
(B) Family 2 pedigree. The asterisk represents an individual whose
family name is identical to that of family 1.
(C) Family 3 pedigree. The polymorphic microsatellite markers and
their location are given at the upper-left and upper-right panel, for
family 2 and family 3, respectively.644 The American Journal of Human Genetics 83, 643–648, NovembHomozygosity mapping with the DNA of three patients
from families 1 and 2, individuals 2761, 1211 and 122, on
GeneChip HumanMapping 250KNsp Array of Affymetrix,
was performed as previously described.5 All experiments
involving DNA of the patients, their relatives, healthy con-
trols, and patients’ cells were approved by the Hadassah
Ethical Review Committee. Multiple genomic stretches of
successive homozygous SNPs, longer than 4Mb, were pres-
ent in the DNA of the three patients but there was only one
homozygous region of identical haplotype. This region
spanned ~16 Mb and consisted of 1309 consecutive SNPs
(59.21–75.17 Mb, rs11076397–rs7500366) on chromo-
some 16. By using polymorphic microsattelite markers in
nonaffected family members, we could narrow it down
to ~13 Mb (62.15–75.17 Mb) (Figure 1A). Within this re-
gion there were 186 ORFs that were prioritized according
to their tissue expression. The sequence of GABARAPL2,
CG1-38, and PLEKHG4 was determined, but no mutation
identiﬁed. We then sequenced the seven exons of FA2H
and their ﬂanking intronic sequences and identiﬁed a
homozygous intronic mutation, c.786þ1G/A. The muta-
tion was present in the seven patients of families 1 and 2
and was not present in a homozygous form in any of the
available unaffected relatives, nor was it present in 110
ethnic-matched control individuals. In cDNA produced
from ﬁbroblasts and fresh blood of the patients, a single
FA2H fragment, 426 bp shorter than the normal fragment
because of exon 5 and 6 skipping, was ampliﬁed (Figures
4A and 4B).
In family 3, the two patients 2327 and 2328 had two
identical regions on chromosome 16: 51.20-58.80 Mb
and 70.74-77.79 Mb (rs3104798–rs10500429 and
rs3852784–rs382888, respectively). Within these regions
there were 118 ORFs that were prioritized according to
their tissue expression. The sequence of the CAPNS2,
PLLP, BOAT, GABARAPL2, and CNTNAP4 genes were deter-
mined but no mutation was identiﬁed. Sequencing the
seven exons of the FA2H gene revealed a homozygous mu-
tation c.103G/T at exon 1 changing a highly conserved
aspartic acid at codon 35 to tyrosine (D35Y) (Figure 4D).
In this family, the parents were heterozygous for the muta-
tion and a healthy sister, asymptomatic at 6 years of age,
had the two normal alleles (Figure 1C).
The human FA2H gene encodes fatty acid 2-hydroxylase,
a 372-amino-acid-long, 43 kDa membrane-bound protein.
It uses free fatty acids as a substrate and the product, free
2-hydroxy fatty acids, is then incorporated into ceramide,
the precursor of GalC. The FA2H protein contains two
conserved domains, a cytochrome b5-like heme-binding
domain that spans residues 15–85 and accounts for the re-
dox activity of FA2H, including its ability to hydroxylate
fatty acids, and a sterol desaturase domain at residues
210–367 (Figure 4C).6,7 We therefore concluded that the
c.786þ1G/A splice-site mutation with the consequent
skipping of exon 5 and 6 (residues 204–346) probably abol-
ishes the catalytic activity; however, a proof of pathogenic-
ity was required for the missense mutation at codon 35. Toer 7, 2008
Table 1. Clinical and Radiological Findings in the Patients
Family-Patient 1-122 1-1211 1-21 2-2761 2-2758 2-2769 2-2762 3-2327 3-2328
Current age 20 18 14 17 11 8 7 12 10



















Spasticity þ þ þ þ þ þ þ þ þ
Dystonia þ þ þ þ þ þ þ  
Cerebellar signs þ þ  þ  þ   
Transfer to special
education
14 11 12 14 RC RC RC RC RC
Wheelchair-bound 14 13 14 12 11 walking walking walking walking
Dysarthria onset 6 7 6 7 5 7 5  
Seizures onset 15   12     
Initial brain MRI findings PPRT PPRT, TCC, CA PPRT, TCC, CA PPRT, TCC, CA PPRT PPRT PPRT not done normal
All numbers refer to age in years, RC, Regular Class; clinical signs are as follows: present (þ) or not present (). PPRT, prolonged periventricular relaxation
time; TCC, thin corpus callosum; and CA, cerebellar atrophy.this end, we transiently transfected COS7 cells with
pcDNA3-hFA2H-mut, which contained the D35Y muta-
tion generated by site-directed mutagenesis.8 Western-
blot analysis with anti-human FA2H polyclonal antibody6
revealed a normal immune reactive protein. To determine
Figure 2. Electron Micrograph of the Sural Nerve Showing
Normal Structure and Distribution of Myelinated and Unmy-
elinated Nerve Fibers
The inset shows details of a myelin sheath to show normal compac-
tion and periodicity of myelin lamellae.The Americafatty acid 2-hydroxylase activity in vitro, we quantiﬁed
conversion of [3,3,5,5-D4] tetracosanoic acid to 2-hydroxy
[3,3,5,5-D4] tetracosanoic acid by gas chromatography-
mass spectrometry as previously described.9 This analysis
showed that the activities of cells expressing the mutant
FA2H were indistinguishable from the COS7 cells trans-
fected with an empty vector, whereas expression of the
wild-type FA2H resulted in over 2-fold increase above the
endogenous level, suggesting that the D35Y mutation in-
activated FA2H.
Heretofore, FA2H was considered to be the only enzyme
active toward straight-chain fatty acids in human. There
are three types of fatty acid 2-hydroxylases known to
date: (1) the di-iron-containing monooxygenases, such as
FA2H, which has no known homologs in human and
mouse,10 (2) cytochrome P450 that catalyzes the H2O2-de-
pendent 2-hydroxylation of fatty acids in bacteria but is
absent in eukaryotes,11 and (3) the 2-oxoglutarate-depen-
dent oxygenase, phytanoyl-CoA 2-hydroxylase, which is
localized to the peroxisome and does not use straight-
chain fatty acids.12 Consistent with the lack of known
FA2H homologs in human, FA2H is highly expressed
where 2-hydroxy fatty acids are found: in the brain (pri-
marily in oligodendrocytes), in peripheral myelin, and in
skin keratinocytes.10,13 Furthermore, FA2H was shown to
be themajor fatty acid 2-hydroxylase in mouse brain given
that anti-FA2H antibodies inhibited most of the fatty acid
2-hydroxylase activity.10 The fact that peripheral myelin
was spared and that only the brain was affected in our pa-
tients was therefore unexpected and suggested a second
fatty acid 2-hydroxylating activity in human. To clarify
this issue, we measured the fatty acid 2-hydroxylation in
cultured skin ﬁbroblasts of the patients and controls by
using deuterated tetracosanoic acid as a substrate and dis-
covered that the amount of labeled 2-hydroxy-tetracosa-
noic acid was slightly higher in the patients than in the
controls (0.178 pmol/min/mg protein in a family 1 pa-
tient, 0.127 pmol/min/mg protein in a family 3 patient,
and a mean value of 0.113 pmol/min/mg protein in twon Journal of Human Genetics 83, 643–648, November 7, 2008 645
Figure 3. Brain MRI of Patient 2762
at 7 Years of Age and Patient 1211 at
18 Years of Age
(A) Sagittal T1 weighted image.
(B) Axial T2 weighted image.
(C and D) Axial FLAIR images showing pro-
longed relaxation times in the periventric-
ular white matter, more prominent posteri-
orly, and to a lesser extent in the posterior
limbs of the internal capsules. There is
no significant loss of volume. Images in
(A)–(D) are of patient 2762 at 7 years of
age.
(E and F) Sagittal T1 weighted (E) and axial
T2 weighted (F) images showing loss of
volume of the corpus callosum and to a
lesser extent of the cerebellum and pons.
Images are of patient 1211 at 18 years of
age.separate normal ﬁbroblast cell lines). Because family 1’s
patients are homozygous for a deleterious mutation at
the FA2H gene, these results are supportive of an addi-
tional fatty-acid-hydroxylation activity that is probably ex-
Figure 4. Mutations in the FA2H Gene
(A) A cDNA fragment of the FA2H gene from the patients of family
1 and 2 who are homozygous for the c.786þ1G/A mutation. Lane
1 represents the control, lane 2 represents the patient, and lane
3 represents the DNA ladder marker.
(B) Sequence of the short cDNA fragment demonstrating exon 5
and 6 skipping.
(C) Schematic representation of the conserved domains of the
FA2H protein. Cyt-b5 stands for cytochrome b5-like heme-binding
domain and ERG3 is the sterol desaturase domain. The locations of
the residues encoded by exon 5 and 6 and of the two mutations are
shown.
(D) Conservation throughout evolution of the aspartic acid at
codon 35 (in bold), which is mutated in patients from family 3.646 The American Journal of Human Genetics 83, 643–648, Novembpressed in human ﬁbroblasts but not in human brain and
may explain peripheral myelin sparing.
Myelinogenesis in human brain starts prenatally
at ~20 weeks of gestation and continues at a signiﬁcant
rate till 5–6 years of age.14 The galactolipids are major con-
stituents of the lipid fraction of myelin and half of their
fatty acids are hydroxylated at their C2 position.15,16 The
proportion of 2-hydroxy to nonhydroxy galactolipids in
rat and mouse brain increases 6- to 8-fold with age and
parallels the expression of myelin protein genes.10,15 These
data suggest a role for 2-hydroxylation in myelin matura-
tion; studies in semi-synthetic 2-hydroxyl galactolipids
revealed that this modiﬁcation contributes to the hydro-
gen-bonding network formed between neighboring lipid
molecules.17 That deleterious mutations in the FA2H
gene manifested clinically only when patients were 4–
6 years of age is consistent with this timeline of myelin
formation and with the need for 2-hydroxy galactolipids
at a later stage of this process.
Many forms of genetic leukodystrophy, such as adreno-
leukodystrophy (MIM 300100), Krabbe disease (MIM
245200), and metachromatic leukodystrophy (MIM
250100), are not associated with defective myelin compo-
sition but are rather caused by a toxic effect of the accumu-
latingmaterial on themyelin-forming cells.18,19 Mutations
in the PLP1 gene that encodes the major structural protein
of central myelin, protein lipid protein 1, are the only
known deﬁciency of a myelin structural component in
human. The clinical phenotypes range from the severe
connatal leukodystrophy, Pelizaeus-Merzbacher disease
(PMD [MIM 312080]), to a milder x-linked spastic parapa-
resis (SPG2 [MIM 312920]).20 To our knowledge, FA2H
deﬁciency is the ﬁrst identiﬁed deﬁciency in the lipid com-
partment of myelin in human. We speculate that the rela-
tively milder phenotype of complete FA2H deﬁciency,er 7, 2008
compared to the severe phenotype of complete PLP1 deﬁ-
ciency (PMD), might be partly attributed to the timeline of
myelin assembly; the bulk of myelin lipids are added at
a late stage of myelin assembly and their entry is directed
by the already present proteins.21 We propose that the se-
vere FA2H mutation associated with leukodystrophy and
its allelic, milder mutation, associated with spastic parapa-
resis are analogous to PMD and SPG2 as well as to
MITCHAP60 disease (MIM 612233) and SPG13 (MIM
605280).22 In these three allelic couples, the severe muta-
tions cause leukodystrophy, whereas the milder mutations
cause spastic paraplegia.
We conclude that mutations in the FA2H gene are asso-
ciated with a progressive neurologic disorder manifested
by spasticity, dystonia, and white matter degeneration.
This is the seventeenth locus associated with an autoso-
mal-recessive complex spastic paraparesis,23 and SPG35
may even be an allelic form.24 Nonetheless, because of
the prominent additional symptoms and the role of
FA2H in myelinogenesis, FA2H deﬁciency should be re-
garded as a new form of leukodystrophy.
Given the long presymptomatic period in our patients
and the full penetrance of their disease, venues of therapy
should be sought. Administration of 2-OH fatty acids could
be considered with caution because of the potential toxic-
ity of 2-OH fatty acids outside of the ER, the site of GalC
synthesis.25 Notably, other myelin sphingolipids, sphingo-
myelin, and complex glycolipids, which are synthesized in
the Golgi apparatus, do not contain 2-OH fatty acids. The
observation of minor expression of FA2H in primary
microglia10 raises the possibility of hematopoeitic stem
cell transplantation. The safety and efﬁcacy of these
options should be clariﬁed in an animal model.
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